

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM626944

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	Business Transfer and Contribution Agreement
RESUBMIT DOCUMENT ID:	900586116

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Covis Pharma B.V.		11/13/2020	Corporation: NETHERLANDS

RECEIVING PARTY DATA

Name:	Covis Pharma GmbH
Street Address:	Grafenauweg 12
City:	Zug
State/Country:	SWITZERLAND
Postal Code:	6300
Entity Type:	Limited Liability Company: SWITZERLAND

PROPERTY NUMBERS Total: 14

Property Type	Number	Word Mark
Registration Number:	2911749	ALTOPREV
Registration Number:	3573087	ALVESCO
Registration Number:	2860362	ALVESCO
Registration Number:	1504551	BETAPACE
Registration Number:	2711659	BETAPACE AF
Registration Number:	4756220	COVIS
Registration Number:	4193537	COVIS P H A R M A
Registration Number:	3650673	
Registration Number:	3574160	OMNARIS
Registration Number:	1866694	RILUTEK
Registration Number:	1939088	SULAR
Registration Number:	4206289	ZETONNA
Registration Number:	2383531	ZANAFLEX
Registration Number:	3341341	ZANAFLEX CAPSULES

CORRESPONDENCE DATA

Fax Number: 9735972400

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

TRADEMARK

Phone: 973-597-2500
Email: lstrademark@lowenstein.com
Correspondent Name: Matthew Hintz, Esq.
Address Line 1: c/o Lowenstein Sandler LLP
Address Line 2: One Lowenstein Drive
Address Line 4: Roseland, NEW JERSEY 07068

ATTORNEY DOCKET NUMBER: 36217.348

NAME OF SUBMITTER: Matthew Hintz

SIGNATURE: /Matthew Hintz/

DATE SIGNED: 02/18/2021

Total Attachments: 19

source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page1.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page2.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page3.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page4.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page5.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page6.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page7.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page8.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page9.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page10.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page11.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page12.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page13.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page14.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page15.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page16.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page17.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page18.tif
source=Business Transfer and Contribution Agreement (Executed) - Copy_Redacted#page19.tif

Business Transfer and Contribution Agreement

THIS AGREEMENT has been entered into on the 13th day of November 2020, by and between Covis Pharma B.V., a private company with limited liability incorporated under the laws of the Netherlands (besloten vennootschap met beperkte aansprakelijkheid), having its official seat (statutaire zetel) in Baarn, the Netherlands, and its office at Gustav Mahlerplein 2, 1082 MA, Amsterdam, the Netherlands, registered with the Dutch Trade Register of the Chamber of Commerce under number 62105809 (the “**Parent**”), and Covis Pharma GmbH, a limited liability company (Gesellschaft mit beschränkter Haftung) incorporated under the laws of Switzerland, having its registered office at Grafenauweg 12, 6300 Zug, Switzerland, registered with the commercial register of the Canton of Zug under number CHE 403-495-189 (the “**Swiss Subsidiary**”).

The Parent has since 20 March 2017 operated through a branch office in Zug, Switzerland, registered with the commercial register of Canton of Zug under the name Covis Pharma B.V., Baarn, Zug Branch and registration number CHE-315.917.995 (the “**Swiss Branch**”). The Parent, acting through its Swiss Branch, maintains an office located in leasehold premises, holds various intellectual property and other assets, employs personnel, enters into contractual relationships, and otherwise engages in business.

The **Swiss Subsidiary** was incorporated on November 6, 2020, and registered with the commercial register of the Canton of Zug on November 10, 2020, as a wholly-owned subsidiary of the Parent.

The Parent desires to transfer and contribute substantially all of the assets and liabilities of the Swiss Branch, subject to certain liabilities, to its Swiss Subsidiary, on the terms and subject to the conditions set forth in this Agreement.

NOW, THEREFORE, the Parent and its Swiss Subsidiary hereby agree as follows:

- 1. Definitions.** The following capitalized terms, when used in this Agreement, have the following meanings:

Agreement means this Business Transfer and Contribution Agreement.

Assigned Contracts means all contracts, agreements and other contractual arrangements that are (i) listed on Schedule 1 or (ii) entered into by the Parent, acting through its Swiss Branch, in the ordinary course of the Business as of the Contribution Date, in each case including all rights and obligations thereunder.

Assumed Liabilities means (i) all liabilities of the Parent assumed through its Swiss Branch under or in respect of the Assigned Contracts, including all Payables thereunder and the prospective obligations assumed by the Parent acting through its Swiss Branch to perform such Assigned Contracts, (ii) the Guarantee, and (iii) all other liabilities of the Parent assumed through its Swiss Branch that have arisen in the ordinary course thereof and remained undischarged (in whole or in part) as of the Effective Date, but excluding the Excluded Liabilities.

Bank Accounts means the bank accounts maintained by the Swiss Branch at the Union Bank of Switzerland (UBS) and Credit Suisse, including all deposits held therein.

Branch Employees means the employees of the Swiss Branch, as listed on Schedule 2.

Business means the business of the Swiss Branch, as it is being conducted on the date of this Agreement.

Business Day means any day (other than a Saturday, Sunday or public holiday in Zug, Switzerland) during which banks in Amsterdam, the Netherlands, and Zug, Switzerland are open for normal business.

CO means the Swiss Code of Obligations.

Completion means the completion of the Contribution.

Contribution has the meaning given to it in clause 2.

Contribution Date means November 16, 2020, or such other date as the parties may agree in writing.

Credit Agreement means the Credit Agreement originally dated as of March 10, 2020, and amended and restated on November 16, 2020, among Covis Finco S.à r.l., as Borrower thereunder, Covis Midco 2 S.à r.l., the Lenders, and Capital One, National Association, as the Administrative Agent and Collateral Agent thereunder, as the same may be amended, restated, supplemented or otherwise modified.

Effective Date means November 1, 2020.

Encumbrance means a mortgage, charge (fixed or floating), pledge, lien, option, hypothecation, restriction, right to acquire, right of pre-emption or interest (legal or equitable) including any assignment by way of security, reservation of title, guarantee, trust, right of set off or other third party right or any other security interest having a similar effect howsoever arising.

Excluded Liabilities means (i) liabilities under or in respect of contracts that were entered into by the Swiss Branch but were assigned to another affiliate of the Parent prior to the date of this Agreement, and (ii) tax liabilities of or in respect of the Branch's operations prior to the Contribution Date.

Guarantee means the guarantee of the Swiss Subsidiary, dated the Contribution Date, in favor of the Lenders and in the form attached as Exhibit A.

Intellectual Property means all intellectual property rights, including:

- (a) patents, trademarks, business names, domain names, trade and service marks and all goodwill associated therewith, copyrights, rights in designs, rights in inventions, database rights and topography rights, in each case whether or not registered;
- (b) applications for any of the rights in (a) above, together with the right to apply for registration of such rights;
- (c) know-how, trade secrets, confidential information, technical information, customer and supplier lists and any other proprietary knowledge and/or information of whatever nature and howsoever arising,

together with any rights or types of protection of the same or a similar nature to those listed in (a), (b) or (c) which may subsist anywhere in the world, including moral rights, rights to royalties, fees, income, payments and other proceeds now or hereafter due or payable with respect to any and all of the foregoing, any and all claims, warranties, credits, causes of action and rights with respect to any of the foregoing, including in each case rights to set-off, indemnity, warranty, reimbursement, refunds, recoupment, damages specific performance or other equitable relief and all other rights of enforcement or recovery from or against any third party regardless of whether or not such rights are currently exercisable or such claims have been asserted, and all rights from which all or any of the foregoing rights derive priority and all rights deriving priority from any of the foregoing and in each case for their full term and/or effect.

Inventory means all inventory, stock and work in progress held or owned by the Swiss Branch in connection with its Business, wherever located, as at the Contribution Date.

IT Systems means all network and information systems, including all computer hardware and mobile devices and software (including associated user manuals, object code and source code and other related materials) owned, used, leased or licensed by the Parent acting through its Swiss Branch.

Landlord means the landlord under each of the Leases.

Leases means the two lease agreements set forth on Schedule 3.

Lenders means HPS Investment Partners, LLC (acting through such of its affiliates, affiliated or managed funds and separately managed accounts as it deems appropriate), Capital One, National Association, and such other Lenders as may from time to time be party to the Credit Agreement.

Payables means all amounts owed by the Parent acting through its Swiss Branch under the Assumed Contracts, or otherwise incurred and owed by the Parent acting through its Swiss Branch in the ordinary course of the Business, as at the Contribution Date.

Receivables means all amounts owing to the Parent acting through its Swiss Branch under the Assumed Contracts, or otherwise earned and owed to the Parent acting through its Swiss Branch in the ordinary course of the Business, as at the Contribution Date (whether or not invoiced and whether or not due and payable at that time).

Records means all accounts, books, ledgers, financing and other records of whatsoever kind, of the Parent in relation to its Swiss Branch and its Business, in each case howsoever stored.

SMA means the Swiss Federal Act on Merger, Demerger, Transformation and Asset Transfer.

Swiss Ruling Application means the application filed by Parent on October 5, 2020 with respect to the transfer of the Swiss Branch to the Swiss Subsidiary.


Tangible Branch Assets means all Inventory, IT Systems, machinery, tools, fixtures and fittings, office equipment, chattels, computer hardware and software, stationery, office consumables and other similar articles owned and used or for use by the Parent acting through its Swiss Branch in connection with the Business at the Contribution Date.

Transferred Assets means the Transferred IP, Tangible Branch Assets, Bank Accounts, Assigned Contracts, Leases, Receivables, and including any other assets contemplated to be transferred in the Swiss Ruling Application.

Transferred IP means the Intellectual Property owned or licensed by the Parent acting through its Swiss Branch and used in the Business, including the Intellectual Property listed or described on Schedule 4 and all other Intellectual Property that the parties hereto hereafter agree should have been included on Schedule 4.

2. Contribution of the Transferred Assets and Assumed Liabilities.


- 2.1 On the terms and subject to the conditions set forth in this Agreement, the Parent herewith agrees to contribute, transfer, assign, deliver and otherwise convey, by way of singular succession, to its Swiss Subsidiary, on the Contribution Date, all of the Transferred Assets and the Assumed Liabilities, with a view to the Swiss Subsidiary carrying on the Business of the Swiss Branch from and after the Contribution Date, and the Swiss Subsidiary herewith agrees to accept and assume the Transferred Assets and the Assumed Liabilities on the Contribution Date (the “**Contribution**”).




5. Completion.

- 5.1 Completion shall take place on the Contribution Date, in advance of which date the Parties shall update any of the Exhibits and/or Schedules to this Agreement as is necessary to accurately reflect the Transferred Assets and Assumed Liabilities being transferred.
- 5.2 Subject to the occurrence and effective as of the Contribution Date, the Parent hereby transfers and assigns all of the Transferred Assets, including all rights, title and interest therein (to the extent the Transferred Assets are not conveyed or transferred in another form) to the Swiss Subsidiary and the Swiss Subsidiary hereby accepts and assumes the Transferred Assets. This Agreement shall constitute a deed of transfer and assignment to procure the transfer of all relevant Transferred Assets that are claims and rights, including claims and rights that have arisen under the Assigned Contracts on or prior to the Effective Date. The

Parent shall comply with and take and implement any other or further transfer action that is required under applicable laws, under any contract or otherwise to fully implement, give full effect to and complete the transfer of the relevant Transferred Assets.



- 
- 5.7 The parties shall execute and the Parent shall deliver to the Swiss Subsidiary such other documentation or instrument as the parties deem necessary or appropriate to consummate the Contribution on the Contribution Date.
- 5.8 The parties intend that the assignment of the Transferred Assets to the Swiss Subsidiary and the assumption by the Swiss Subsidiary of the Assumed Liabilities shall be given economic effect from, and as of, the Effective Date. All benefits, risks and opportunities of the Business will be for the account of the Swiss Subsidiary from, and as of, the Effective Date. Consequently, all relevant acts and transactions from, and as of, the Effective Date are deemed to be made on behalf of the Swiss Subsidiary and will be booked in the accounts accordingly with the profits and losses generated in the Business from, and as of, the Effective Date being recorded in the profit and loss statement of the Swiss Subsidiary. Without limiting the foregoing, if and to the extent that the Parent suffers any loss, or receives any gain, from the Business during the period between the Effective Date and the Contribution Date, to the extent not otherwise reimbursed or compensated by the other provisions of this Agreement, the Swiss Subsidiary shall reimburse the Parent, or the Parent shall transfer to its Swiss Subsidiary, the amount necessary to put the Parent or its Swiss Subsidiary in the economic position it would have been in had the Contribution Date been the Effective Date.
- 6. Counterparty Consents.** Notwithstanding clause 5, this Agreement does not constitute an assignment or an attempted assignment of an Assigned Contract if the assignment or attempted assignment thereof would constitute a breach of that Assigned Contract, and in such cases:
- 6.1 the parties shall each use their reasonable endeavors to obtain any third party consent or waiver required to lawfully assign such Assigned Contract; and
- 6.2 with economic effect from the Effective Date, unless and until such Assigned Contract is assigned to the Swiss Subsidiary:
- (i) the Parent shall hold such Assigned Contract on trust for its Swiss Subsidiary and will account to the Swiss Subsidiary for any sums or other benefits received by the Parent in relation to such Assigned Contract without any deduction or withholding of any kind;
 - (ii) the Swiss Subsidiary shall, as its Parent's agent, perform all obligations of the Parent under any such Assigned Contract; and
 - (iii) the Parent shall do each act and thing reasonably requested of it by its Swiss Subsidiary to provide for the Swiss Subsidiary the benefit, use and enjoyment of such Assigned Contract and the right to receive any income from such Assigned Contract and to enable the Swiss Subsidiary to enforce any right or claim in relation to such Assigned Contract.
- 7. Post-Completion.**

7.1 If any Transferred Assets or Assumed Liabilities are not transferred to the Swiss Subsidiary for any reason at Completion and continue to be held by the Parent, then the party that discovers that such Transferred Assets or Assumed Liabilities have not been transferred shall promptly inform the other party of that fact. Thereafter, at the request of the Swiss Subsidiary, the Parent undertakes without any consideration to execute or procure the execution of such documents and to take such action as may be reasonably necessary to procure the transfer of any such Transferred Assets or Assumed Liabilities to the Swiss Subsidiary.


7.2 In the event that either party discovers that any kind of asset unrelated to the Business is transferred to the Swiss Subsidiary at Completion, the party that discovers that such assets have inadvertently transferred shall promptly inform the other party of that fact. Thereafter, at the request of the Parent, the Swiss Subsidiary undertakes without any consideration to execute or procure the execution of such documents and to take such action as may be reasonably necessary to procure the transfer of any such asset to the Parent.

8. Risk and Benefit.

8.1 Benefit and risk (Nutzen und Gefahr) in respect of all the Transferred Assets and the Assumed Liabilities shall pass to the Swiss Subsidiary as of the Effective Date.

8.2 The parties shall make the necessary adjustment payment(s) to each other in order to reflect the above allocation of risk and benefit and to correct for any erroneous payment by third parties. Neither party shall charge any cost for such payments.

9. Representation and Warranties. The parties hereby explicitly exclude any representation and warranties with respects to the Business, the Transferred Assets and the Assumed Liabilities. All remedies, including the right to rescind this Agreement following Completion, shall not apply and are hereby explicitly waived. In particular, and without limitation to the foregoing, the parties hereby explicitly waive the applicability of article 23 CO, article 24 CO, article 97 CO and article 197 et seq. CO.



11. Transfer of the Intellectual Property. Parent shall from time to time, at the request of and without further cost or expense to the Swiss Subsidiary, execute, acknowledge and deliver such other further assignments, conveyances, and other assurances, documents, and instruments of transfer reasonably requested by the Swiss Subsidiary in connection with the Transferred IP, and

take such other actions consistent with the terms of this Agreement as may reasonably be requested in order to assign, transfer, grant, convey, and confirm to Swiss Subsidiary the Transferred IP or otherwise consummate the transactions contemplated hereby. In particular, the Parent shall, as the case may be, sign all documents, make all declarations and take all actions which are necessary or appropriate for the registration of the Swiss Subsidiary, and the cancellation of the Parent, in and from relevant registers regarding the Transferred IP.

12. Taxes. Each party shall pay its own taxes, if any, in relation to the transactions contemplated by this Agreement. In relation to Swiss VAT, the parties agree that the notification procedure pursuant to section 38 of the VAT Act shall be applicable

13. General.

13.1 Neither party shall assign, transfer, charge, make the subject of a trust or deal in any other manner with this Agreement or any of its rights under this Agreement or purport to do any of the same without the prior written consent of the other party; provided that, notwithstanding anything to the contrary in this Agreement, either party may collaterally assign its rights under this Agreement to the Collateral Agent under the Loan Documents (as defined in the Credit Agreement).

13.2 This Agreement shall be binding upon and shall survive for the benefit of the personal representatives and successors-in-title of each party.

13.3 No person who is not a party to this Agreement shall have any rights under this Agreement, including any right to enforce or rely on a provision of this Agreement.

13.4 This Agreement, together with all documents entered into or to be entered into pursuant to the terms of this Agreement, constitutes the entire agreement between the parties with respect to all matters referred to in this Agreement. This Agreement supersedes and extinguishes all previous agreements between the parties relating to such matters.

13.5 No amendment of or variation to this Agreement shall be effective unless made in writing and signed by or on behalf of each of the parties.

13.6 Each provision of this Agreement is severable and distinct from the others. If at any time any provision of this Agreement is or becomes unlawful, invalid or unenforceable to any extent or in any circumstances for any reason, it shall to that extent or in those circumstances be deemed not to form part of this Agreement but (except to that extent or in those circumstances in the case of that provision) the legality, validity and enforceability of that and all other provisions of this Agreement shall not be affected in any way.

13.7 Each party shall (at its own expense) promptly execute and deliver such documents, perform such acts and do such things as the other party may reasonably require from time to time for the purpose of giving full effect to this Agreement.

13.8 Unless otherwise provided, all costs and expenses in connection with the negotiation, preparation, execution and performance of this Agreement, and any documents referred to in it, shall be borne by the party that incurred the costs.

13.9 This Agreement may be executed in any number of counterparts, each of which when executed and delivered shall be an original. All the counterparts shall together constitute one and the same

agreement, which shall be deemed executed when counterparts executed by the Parties are delivered.

- 13.10 This Agreement shall be governed by and interpreted in accordance with the substantive laws of Switzerland (to the exclusion of Swiss private international law and of international treaties, in particular, the Vienna Convention on the International Sale of Goods dated 11 April 1980). Non-contractual obligations (if any) arising out of or in connection with this Agreement (including its formation) shall also be governed by the substantive laws of Switzerland (to the exclusion of Swiss private international law and of international treaties, in particular, the Vienna Convention on the International Sale of Goods dated 11 April 1980).
- 13.11 Any and all disputes arising out of or in connection with this Agreement, including but not limited to disputes on the validity, enforceability and termination of this Agreement and the consequences of that termination, shall be submitted to the jurisdiction of competent court in Zug, Switzerland.

[Signature Page Follows]

The parties have caused this Agreement to be executed as of the date first above written.

COVIS PHARMA B.V.
a Dutch corporation

By: _____

Name: *A. Q. BEELAERT van Bickelands*

Title: *Director*

By: _____

Name:

Title:

COVIS PHARMA GMBH
a Swiss limited liability corporation

By: _____

Name:

Title:

By: _____


Name:

Title:

{Project Florence -- Signature Page to the Branch Transfer Agreement}

The parties have caused this Agreement to be executed as of the date first above written.

COVIS PHARMA B.V.
a Dutch corporation

By: 
Name: J. H. J. ZAAAT
Title: DIRECTOR

By: _____
Name:
Title:

COVIS PHARMA GMBH
a Swiss limited liability corporation

By: _____
Name:
Title:

By: _____
Name:
Title:

{Project Florence – Signature Page to the Branch Transfer Agreement}

The parties have caused this Agreement to be executed as of the date first above written.

COVIS PHARMA B.V.
a Dutch corporation

By: _____

Name:

Title:

By: _____

Name:

Title:

COVIS PHARMA GMBH
a Swiss limited liability corporation

By: FABIO FAZIO

Name: FABIO FAZIO

Title: MANAGING DIRECTOR

By: _____

Name:

Title:

{Project Florence – Signature Page to the Branch Transfer Agreement}

SCHEDULE 4
TRANSFERRED IP

List Attached

Schedule 7(a)

Registered Patents and Trademarks

PATENTS AND PATENT APPLICATIONS


US Patents and Patent Applications


Patent	Jurisdiction	Application Number/ Filing Date	Patent Number/ Issue Date	Status	Owner ¹
Aqueous suspensions of ciclesonide for nebulisation	United States	14865637 25-SEP-2015	Not Available	Pending	COVIS PHARMA B. V.
Ciclesonide contained pharmaceutical composition for application to mucosa	United States	10110629 15-JUL-2002	6767901 27-JUL-2004	Registered	COVIS PHARMA B. V.
Ciclesonide containing aqueous pharmaceutical composition	United States	10110632 15-JUL-2002	8383611 26-FEB-2013	Registered	COVIS PHARMA B. V.
Ciclesonide containing sterile aqueous suspension	United States	12448351 21-AUG-2009	8481516 09-JUL-2013	Registered	COVIS PHARMA B. V.
Ciclesonide-containing sterile aqueous suspension	United States	12461647 19-AUG-2009	8268240 18-SEP-2012	Registered	COVIS PHARMA B. V.
Ciclesonide-containing sterile aqueous suspension	United States	10519484 21-JUL-2005	8182824 22-MAY-2012	Registered	COVIS PHARMA B. V.
Combination medicament	United States	12973350 20-DEC-2010	8258124 04-SEP-2012	Registered	COVIS PHARMA B. V.
Combination medicament	United States	10537356 03-JUN-2005	7879833 01-FEB-2011	Registered	COVIS PHARMA B. V.
Combination of riluzole and of gabapentin and its use as a medicament	United States	09718543 22-NOV-2000	6350768 26-FEB-2002	Registered	COVIS PHARMA B. V.
Compliance monitor and method	United States	10572316	8464707 18-JUN-2013	Registered	COVIS PHARMA B. V.

¹ All patents and patent applications will be transferred to Covis Pharma GmbH in connection with the Restructuring Transactions.

Patent	Jurisdiction	Application Number/ Filing Date	Patent Number/ Issue Date	Status	Owner ¹
Formoterol of and ciclesonide combination	United States	10559383 06-DEC-2005	8435497 07-MAY-2013	Registered	COVIS PHARMA B. V.
Metered dose inhaler	United States	29283277 09-AUG-2007	D582544 09-DEC-2008	Registered	COVIS PHARMA B. V.
Pharmaceutical aerosol product for administration by oral or nasal inhalation	United States	14238055 10-FEB-2014	Not Available	Pending	COVIS PHARMA B. V.
Process for preparing crystalline ciclesonide with defined particle size	United States	10549631 07-NOV-2005	9422327 23-AUG-2016	Registered	COVIS PHARMA B. V.
Process for the production of 16,17-[(cyclohexylmethyl)bis(oxy)]-1,1,2,1-dihydroxy-pregna-1,4-dien-3,20-dion or its 21-isobutylrat by transketalisation	United States	10399689 04-AUG-2003	7468433 23-DEC-2008	Registered	COVIS PHARMA B. V.
Rituzole and alpha-tocopherol combination	United States	09854318 11-MAY-2001	6642262 04-NOV-2003	Registered	COVIS PHARMA B. V.
Stabilized pharmaceutical product	United States	13437569 02-APR-2012	8440210 14-MAY-2013	Registered	COVIS PHARMA B. V.
Stabilized pharmaceutical product	United States	13219046 26-AUG-2011	8163299 24-APR-2012	Registered	COVIS PHARMA B. V.
Stabilized pharmaceutical product	United States	12771557 30-APR-2010	8029811 04-OCT-2011	Registered	COVIS PHARMA B. V.
Stabilized pharmaceutical product	United States	11259495 26-OCT-2005	7736673 15-JUN-2010	Registered	COVIS PHARMA B. V.
Stable pharmaceutical products	United States	12951608 22-NOV-2010	8288445 16-OCT-2012	Registered	COVIS PHARMA B. V.
Stable pharmaceutical products	United States	11325875 05-JAN-2006	7947744 24-MAY-2011	Registered	COVIS PHARMA B. V.
Use of ciclesonide for the treatment of respiratory diseases	United States	10571311 09-MAR-2006	8371292 12-FEB-2013	Registered	COVIS PHARMA B. V.
Use of ciclesonide for the treatment of respiratory diseases	United States	16440557 13-JUN-2019	Not Available	Pending	COVIS PHARMA B. V.

Patent	Jurisdiction	Application Number/ Filing Date	Patent Number/ Issue Date	Status	Owner ¹
Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis	United States	12973414 20-DEC-2010	8486923 16-JUL-2013	Registered	COVIS PHARMA B. V.
Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis	United States	10524821 18-FEB-2005	7879832 01-FEB-2011	Registered	COVIS PHARMA B. V.







TRADEMARKS

US and Non-US Trademark Registrations and Applications

Mark	Country	Serial No./ Filing Date	Reg. No./ Reg. Date	Status	Owner ¹
ALTOPREV	United States	78236828 11-APR-2003	2911749 14-DEC-2004	Registered	COVIS PHARMA B. V.
ALVESCO	United States	77074621 02-JAN-2007	3573087 10-FEB-2009	Registered	COVIS PHARMA B. V.
ALVESCO					
ALVESCO	United States	78282980 04-AUG-2003	2860362 06-JUL-2004	Registered	COVIS PHARMA B. V.
BETAPACE	United States	73701175 15-DEC-1987	1504551 20-SEP-1988	Registered	COVIS PHARMA B. V.
BETAPACE AF	United States	75817196 06-OCT-1999	2711659 29-APR-2003	Registered	COVIS PHARMA B. V.

Mark	Country	Serial No./ Filing Date	Reg. No./ Reg. Date	Status	Owner ¹
COVIS	United States	85500624 21-DEC-2011	4756220 16-JUN-2015	Registered	COVIS PHARMA B. V.
COVIS					
COVIS PHARMA 	United States	85463181 03-NOV-2011	4193537 21-AUG-2012	Registered	COVIS PHARMA B. V.
Design Only	United States	77635826 18-DEC-2008	3650673 07-JUL-2009	Registered	COVIS PHARMA B. V.
					
OMNARIS	United States	78949782 10-AUG-2006	3574160 10-FEB-2009	Registered	COVIS PHARMA B. V.
OMNARIS					
RILUTEK	United States	74451450 26-OCT-1993	1866694 13-DEC-1994	Registered	COVIS PHARMA B. V.
SULAR	United States	74322049 13-OCT-1992	1939088 05-DEC-1995	Registered	COVIS PHARMA B. V.
ZETONNA	United States	77790189 27-JUL-2009	4206289 11-SEP-2012	Registered	COVIS PHARMA B. V.
ZETONNA					
ZANAFLEX <i>Zanaflex</i>	United States	75186534 15-OCT-1996	2383531 05-SEP-2000	Registered	COVIS PHARMA B. V.
ZANAFLEX CAPSULES	United States	78713378 15-SEP-2005	3341341 20-NOV-2007	Registered	COVIS PHARMA B. V.
ZANAFLEX CAPSULES					